Abstract Details
Activity Number:
|
208
|
Type:
|
Roundtables
|
Date/Time:
|
Monday, August 10, 2015 : 12:30 PM to 1:50 PM
|
Sponsor:
|
Health Policy Statistics Section
|
Abstract #315831
|
|
Title:
|
Statistical Methods for Benefit-Risk Assessment to Meet Regulatory Agency Requirements
|
Author(s):
|
T. Ceesay*
|
Companies:
|
Merck
|
Keywords:
|
benefit risk ;
therapeutic area ;
regulatory
|
Abstract:
|
It is important that both efficacy and safety are taken into consideration when assessing the merit of drugs so that patients are only exposed to drugs for which the benefit outweighs the risk. It is especially important in the current environment, in which "value" (in addition to efficacy and safety) is an integral part of global health policy to assess the practicality of a new drug or therapy. Various comparative benefit-risk methods can be used to assess the superiority of one therapy or drug over another depending on the therapeutic area. The discussion will focus on the statistical methods that have been and can be used for comparative benefit-risk assessment in various therapeutic areas. Challenges of developing and implementing a method for comparative benefit-risk assessment to satisfy regulatory requirements also will be discussed.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2015 program
|
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.